Enjamb Labs
Enjamb Labs is a YC Spring 2026 (P26) company. Based in San Francisco, CA, USA. Team of 2.
About Enjamb Labs
Summary
Enjamb Labs builds an AI agent platform for biopharma teams running drug programs from discovery through FDA approval. Its agents connect to the legacy systems drug teams already use, including Benchling, Veeva, and Medidata, without requiring data migration, and carry out the hands-on work across clinical evidence, trial design, statistical programming, and regulatory submissions. The platform replaces the manual, cross-system coordination that scientists and operations staff perform inside those siloed tools today.
Go-to-market
Enterprise biopharma teams at large pharma companies are the primary buyers, reached through a sales-led motion with a demo booking flow on the site.
From the Y Combinator listing
Where drug teams run their entire program, discovery to FDA approval
Enjamb runs the entire drug program for biopharma teams, from discovery to FDA approval. Pharma runs on decades of closed legacy systems like Benchling, Veeva, Medidata, and SAS, with no AI layer and no MCP to connect agents to them. So we built that connection layer in one platform. Our agents run on top of their existing systems and data, with no migration, and do the work across the whole program: clinical evidence, trial design, statistical programming, and regulatory submissions. In just 3 weeks since launch, we're already being used by 500+ employees at top pharma companies, including Johnson & Johnson, AbbVie, Bristol Myers Squibb, Merck & Sanofi.
Facts
- B2B / B2B
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (2)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works